News

20

Sobhan Oncology Pharmaceutical Co. managed to receive 7 new product Marketing Authorizations from the Iranian Food and Drug Administration as follows:

Imatinib 100 mg and 400 mg tablets, Erlotinib 100 mg and 150 mg tablets, Lenalidomide 10 mg and 25 mg capsules, Bicalutamide 50 mg and 150 mg tablets.
Actions: E-mail | Permalink |
انتخاب رنگ:
عرض اسکین:
پترن زمینه:
ستون های مگا منو:
گزینه جستجو: خروج